Regulatory Agios mulls early FDA filing for sickle cell therapy PharmaphorumAgios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.RegulatoryHematologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months. RegulatoryHematologyRead full story Post navigation Previous: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutNext: A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026